You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Ariad curtails leukemia drug trial on clot risk

Shares of Ariad Pharmaceuticals Inc. tumbled nearly 66 percent Wednesday after the Cambridge biotechnology company said it stopped enrolling patients in ongoing clinical trials of its leukemia drug because new data showed an increased number suffered blood clots and heart problems in an earlier study.

Food and Drug Administration regulators ordered a “partial clinical hold” on Ariad’s trials until the fast-growing company changes its clinical study doses and eligibility rules and the FDA updates a warning label for the drug, called Iclusig, which was approved for US sale last December and remains on the market.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week